The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
51st Annual Meeting of the EBMT congress coverage: Lymphoma (Part 1)
Stay up to date with the latest developments in lymphoma (Part 1) with our live social media coverage from the 51st Annual Meeting of the EBMT, March 30 –April 2, 2025, Florence, Italy.
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 2, 2025
Nicole Santoro, Santo Spirito Hospital presented a retrospective study evaluating the efficacy and safety of brexu-cel in elderly patients aged >70 years with R/R MCL (N=202).
Outcomes at 1 year: OS and PFS were 74% and 65%, respectively.… pic.twitter.com/QV9ffeItre
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 2, 2025
Shan Fu, Hospital Universitari i Politècnic La Fe presented preliminary results from a phase I study evaluating the safety and efficacy of autologous CD7 CAR T-cell therapy for the treatment of patients with R/R T-cell #lymphoma (N=10).
ORR was… pic.twitter.com/boLFum6ZSq
CONGRESS | #EBMT25 | PRESENTATION @dvandersonrocha, São Paulo University presented a study comparing outcomes of tisa-cel vs axi-cel in elderly patients aged >70 years with DLBCL. N=1064,
— Lymphoma Hub (@lymphomahub) April 2, 2025
Outcomes in tisa cel vs axi cel at 1-Year:
OS: 56% vs 63%
PFS: 37% vs 51%
Relapse… pic.twitter.com/WfQdYGCWDo
CONGRESS | #EBMT25 | POSTER
— Lymphoma Hub (@lymphomahub) April 1, 2025
Eugen Leung, @UHN, discusses a case study of severe CAR T-cell therapy related toxicity. The 67-year old patient with mantle cell lymphoma developed Grade 2 CRS within 48 hours post CAR T-cell therapy, followed by Grade 4 ICANS on Day 7 and development… pic.twitter.com/c4dLGzUtU6
CONGRESS | #EBMT25 | POSTER
— Lymphoma Hub (@lymphomahub) April 1, 2025
Liudmila Fedorova, Gorbacheva Research Institute, Pavlov University, shares results of a study comparing second-line (Group 1) versus third- or fourth-line auto-HSCT (Group 2) in patients with R/R classic Hodgkin lymphoma (N = 51) treated with immune… pic.twitter.com/bnNsgqDmVa
CONGRESS | #EBMT25 | POSTER
— Lymphoma Hub (@lymphomahub) April 1, 2025
Nicolás De Lucas Torres, Hospital Universitario Central de Asturias, Oviedo, Spain @uniovi_info, presents findings of a retrospective study assessing the role of inflammatory biomarkers in predicting response to CAR T-cell therapy in patients with… pic.twitter.com/GgEJgtuNhH
CONGRESS | #EBMT25 | POSTER
— Lymphoma Hub (@lymphomahub) April 1, 2025
Ana Benzaquén, Hospital Clinico Universitario de Valencia, Valencia, Spain, shares findings from a retrospective study evaluating infectious episodes in adult patients with R/R Non-Hodgkin lymphoma treated with axi-cel (N = 54). Infectious episodes… pic.twitter.com/l876p5ouQF
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 1, 2025
Jan Schröder, University Hospital Tubingen presented an update on the impact of prior B-cell directed immunotherapy on the outcome of CD19 CAR-T cell therapy in aggressive B-cell malignancies.
Follow our live feed for more updates:… pic.twitter.com/TQxHvGa87x
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 1, 2025
Philipp Berning @UK_Muenster discussed an update on the role of bridging therapy before CAR-T cell therapy in diffuse large B-cell #lymphoma.
Follow our live feed for more updates: https://t.co/fJoKaNsrCt#lymsm #MedicalCongress @TheEBMT pic.twitter.com/VJiw8EQmdV
CONGRESS | #EBMT25 | PRESENTATION
— Lymphoma Hub (@lymphomahub) April 1, 2025
Alberto Mussetti from Hospitalet de Llobregat discussed results from a retrospective multicenter study of Allo-HCT as consolidation therapy in patients with R/R B-NHL who were exposed to CD3-CCD20 bispecific antibodies.
2-Year NRM: 36%… pic.twitter.com/JKlNXq8nfv
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
